Table 5.
Antiproliferative activity of fractions 1–8 evaluated by MTS assays after 72 h of treatment.
| MCF‐7 cell line | MCF‐7R cell line | MDA‐MB‐231 cell line | 1‐7HB2 cell line | |
|---|---|---|---|---|
| FR | IC50 (µg/mL) ± SE | IC50 (µg/mL) ± SE | IC50 (µg/mL) ± SE | IC50 (µg/mL) ± SE |
| 1 | 135.0 ± 39.6 | 168.0 ± 6.0 | 192.0 ± 4.9 | 212.5 ± 5.3 |
| 2 | 65.5 ± 17.3 | 75.0 ± 7.0 | 85.5 ± 0.3 | 97.5 ± 1.8 |
| 3 | 132.0 ± 30.0 | 143.5 ± 15.0 | 184.0 ± 0.7 | 186.5 ± 2.5 |
| 4 | 33.5 ± 9.5 | 43.5 ± 2.5 | 44.5 ± 2.5 | 45.5 ± 3.2 |
| 5 | 69.0 ± 13.4 | 81.0 ± 1.4 | 85.5 ± 0.3 | 98.5 ± 1.1 |
| 6 | 38.0 ± 2.1 | 43.0 ± 2.1 | 62.0 ± 4.9 | 74.0 ± 1.4 |
| 7 | 66.0 ± 8.5 | 38.0 ± 0.7 | 71.5 ± 3.9 | 73.5 ± 2.5 |
| 8 | 36.0 ± 2.1 | 18.5 ± 2.5 | 64.0 ± 4.9 | 46.5 ± 2.5 |
| Doxorubicin | 0.8 ± 0.1 | 37.0 ± 2.0 | 0.05 ± 0.004 | n.t. |
Note: Data are expressed as the IC50 (concentration inhibiting 50% of cell growth) and are the mean ± standard error (SE) of at least three separate experiments. n.t.: not tested.